Innovative drug discovery company Argent BioPharma Ltd (LSE:MXC, OTC:MGCLF, ASX:RGT) has appointed Dr Shlomo Sadoun to its advisory board with immediate effect.
Sadoun has more than 18 years of experience in the pharmaceutical sector and co-founded and leads SK-Pharma Group, a global pharmaceutical company operating in 18 countries. SKPharma specialises in producing and marketing generic, specialty pharma, hybrid generics and biosimilar pharmaceutical products.
Sadoun also serves as the CEO of Arphio, an orphan drug company utilising proprietary technology to promote, market and sell orphan drugs worldwide.
His expertise lies in leveraging technology to redefine business processes. He has established strategic alliances with in excess of 200 innovative companies and launched more than 300 products globally, many of which were pioneering and branded. His adeptness in utilising technological advancements has propelled SK-Pharma to become the fastest-growing pharmaceutical group in Israel and beyond.
Sadoun holds a master’s degree in Global Management from Salford University and a Doctorate in Business Administration from the Royal Academy of Economics and Technology in Switzerland with a focus on public health.
Argent BioPharma managing director Roby Zomer said: “We are delighted to welcome Dr Shlomo Sadoun, an esteemed addition to our advisory board.
“With his wealth of experience and expertise in the pharmaceutical sector, Dr Sadoun will undoubtedly provide invaluable insights and guidance as we embark on our new strategic direction.
“His appointment reaffirms our commitment to fostering a diverse and knowledgeable advisory board, dedicated to driving innovation and growth in our company.”